MR-BIO: a Study to Evaluate Changes in MR Imaging and Biological Parameters

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-20

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The MR BIO study aims to understand the changes in the tumour and normal tissues during a course of radiotherapy. This is accomplished by studying the MR images taken during each treatment session on the MR Linear accelerator (MR Linac). The overarching hypothesis is that changes in MR imaging and biological parameters from blood, tissue, or urine biomarkers can be measured during radiotherapy and associated with clinical outcome.

The MR Linac is a new radiotherapy machine with an on board MR scanner. This enables us to take images with high resolution and target the tumours more precisely and also reduce the dose to normal tissues. All patients undergoing treatment in the MR Linac at the Christie hospital will be considered for enrolment regardless of tumour site being treated.

The study participants will receive the standard of care treatment for their disease condition. In addition, they will be requested to give weekly blood and urine samples during the course of radiotherapy and at first follow up. On completion of radiotherapy treatment, the participants will continue to be on standard of care follow up protocol with the treating oncologist.

A small cohort of ten healthy volunteers will also be recruited to the study to develop and select some of the MR sequences only; they will not provide blood or urine samples. The healthy volunteers will be scanned for no more than one hour per session for a maximum of two sessions in total. These optimised sequences can then be used in the patient cohort.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment

NCT04803084

Breast Cancer Triple-negative Breast Cancer

SUSPENDED

Magnetic Resonance Imaging of Breast Cancer

NCT01035112

Breast Cancer Breast Cancer Non-invasive Breast Cancer

RECRUITING NA

Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts

NCT02933489

Asymptomatic

ACTIVE_NOT_RECRUITING NA

Integrin α6-targeted SPECT Imaging of Breast Cancer

NCT04289532

Breast Cancer

COMPLETED EARLY_PHASE1

Radiomics of Mp-MRI Assessing NAC Outcome in Breast Cancer

NCT03592004

Breast Cancer Radiomics Neoadjuvant Chemotherapy +1 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-patient healthy volunteer

Undertake MR Imaging to enable development of sequences.

No interventions assigned to this group

Patient

Provide weekly blood and urine samples during period of radiotherapy as well as additional MR images.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Be willing and able to provide written consent. Over 18 years of age. Undergo and satisfy MRI Safety Screening Patient volunteers must be under the care of a clinical oncologist at The Christie NHS Foundation Trust and be planned to receive radiotherapy to the target site to be imaged.

Patient volunteers must be able to give blood and/or urine sample as required through the treatment period.

Non-patient (healthy) volunteers must have no known or suspected significant medical condition.

Exclusion Criteria

The following apply to both patients and healthy volunteers:

Any conditions that would be a contra-indication to MRI including:

* Failure to satisfy MRI Safety Screening Form
* Implanted pacemakers and/or pacing wires
* Cochlear implants
* Programmable hydrocephalus shunts
* Ferromagnetic implants
* Unable to tolerate MR scans
* Known HIV or active HepB or C
* Pregnancy Healthy volunteers must not be a member of the study team.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes